Monobenzone

{{DrugProjectFormSinglePage |authorTag=Ammu Susheela, M.D. [1] |genericName=Monobenzone |aOrAn=a |drugClass=hypopigmentation agent |indicationType=treatment |indication=for final depigmentation in extensive vitiligo |adverseReactions=achromia of skin, permanent, burning sensation, dermatitis, skin irritation, transient |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=ConditionName:

• Content

|fdaLIADAdult=* Benoquin Cream 20% is indicated for final depigmentation in extensive vitiligo.

• Benoquin Cream 20% is applied topically to permanently depigment normal skin surrounding vitiliginous lesions in patients with disseminated (greater than 50 percent of body surface area) idiopathic vitiligo.
• Benoquin Cream 20% is not recommended in freckling; hyperpigmentation caused by photosensitization following the use of certain perfumes (berlock dermatitis); melasma (chloasma) of pregnancy; or hyperpigmentation resulting from inflammation of the skin. Benoquin Cream 20% is not effective for the treatment of cafe-au-lait spots, pigmented nevi, malignant melanoma or pigmentation resulting from pigments other than melanin (e.g.: bile, silver, or artificial pigments).
• A thin layer of Benoquin Cream 20% should be applied and rubbed into the pigmented area two or three times daily, or as directed by physician. Prolonged exposure to sunlight should be avoided during treatment with Benoquin Cream 20%, or a sunscreen should be used.
• Depigmentation is usually accomplished after one to four months of Benoquin Cream 20% treatment. If satisfactory results are not obtained after four months of Benoquin Cream 20% treatment, the drug should be discontinued. When the desired degree of depigmentation is obtained, Benoquin Cream 20% should be applied only as often as needed to maintain depigmentation (usually only two times weekly).

|offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Monobenzone in adult patients.

|offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Monobenzone in adult patients.

|fdaLIADPed=There is limited information regarding FDA-Labeled Use of Monobenzone in pediatric patients.

|offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Monobenzone in pediatric patients.

|offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Monobenzone in pediatric patients.

|contraindications=* Benoquin Cream 20% contains a potent depigmenting agent and is not a cosmetic skin bleach. Use of Benoquin Cream 20% is contraindicated in any conditions other than disseminated vitiligo. Benoquin Cream 20% frequently produces irreversible depigmentation, and it must not be used as a substitute for hydroquinone.

• Benoquin Cream 20% is also contraindicated in individuals with a history of sensitivity or allergic reactions to this product, or any of its ingredients.

|warnings=* Benoquin Cream 20% is a potent depigmenting agent, not a mild cosmetic bleach. Do not use except for final depigmentation in extensive vitiligo.

• Keep this, and all medications out of the reach of children. In case of accidental ingestion, call a physician or a Poison Control Center immediately.

|clinicalTrials=There is limited information regarding Clinical Trial Experience of Monobenzone in the drug label. |postmarketing=* Mild, transient skin irritation and sensitization, including erythematous and eczematous reactions have occurred following topical application of Benoquin Cream 20%. Although those reactions are usually transient, treatment with Benoquin Cream 20% should be discontinued if irritation, a burning sensation, or dermatitis occur. Areas of normal skin distant to the site of Benoquin Cream 20% application frequently have become depigmented, and irregular, excessive, unsightly, and frequently permanent depigmentation has occurred. |drugInteractions= |FDAPregCat=C |useInPregnancyFDA=* Animal reproduction studies have not been conducted with Benoquin Cream 20%. It is also not known whether Benoquin Cream 20% can cause fetal harm when administered to a pregnant woman, or can affect reproduction capacity. Benoquin Cream 20% should be given to a pregnant woman only if clearly needed. |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Monobenzone in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Monobenzone during labor and delivery. |useInNursing=* It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Benoquin Cream 20% is administered to a nursing woman. |useInPed=The safety and effectiveness of Benoquin Cream 20% in pediatric patients below the age of 12 years have not been established. |useInGeri=There is no FDA guidance on the use of Monobenzone with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Monobenzone with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Monobenzone with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Monobenzone in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Monobenzone in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Monobenzone in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Monobenzone in patients who are immunocompromised.

|administration=* Topical |monitoring=There is limited information regarding Monitoring of Monobenzone in the drug label.

• Description

|IVCompat=There is limited information regarding IV Compatibility of Monobenzone in the drug label.

|drugBox= |mechAction=* Benoquin Cream 20% is a depigmenting agent whose mechanism of action is not fully understood.

• The topical application of monobenzone in animals, increases the excretion of melanin from the melanocytes. The same action is thought to be responsible for the depigmenting effect of the drug in humans. Monobenzone may cause destruction of melanocytes and permanent depigmentation. This effect is erratic and may take one to four months to occur while existing melanin is lost with normal sloughing of the stratum corneum. Hyperpigmented skin appears to fade more rapidly than does normal skin, and exposure to sunlight reduces the depigmenting effect of the drug. The histology of the skin after depigmentation with topical monobenzone is the same as that seen in vitiligo; the epidermis is normal except for the absence of identifiable melanocytes.

|structure=* Monobenzone is the monobenzyl ether of hydroquinone. Monobenzone occurs as a white, almost tasteless crystalline powder, soluble in alcohol and practically insoluble in water.

• Chemically, monobenzone is designated as p-(benzyloxy) phenol; the empirical formula is C13H12O2; molecular weight 200.24. The structural formula is:

This image is provided by the National Library of Medicine.

• Each gram of Benoquin Cream contains 200 mg of monobenzone USP, in a water-washable base consisting of purified water USP, cetyl alcohol NF, propylene glycol USP, sodium lauryl sulfate NF and white wax NF.

|PD=There is limited information regarding Pharmacodynamics of Monobenzone in the drug label.

|PK=There is limited information regarding Pharmacokinetics of Monobenzone in the drug label.

|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Monobenzone in the drug label.

|clinicalStudies=There is limited information regarding Clinical Studies of Monobenzone in the drug label.

|howSupplied=* Benoquin Cream 20% in 1 1/4 oz. tubes (35.4 g) (NDC 0187-0380-34). |storage=* Benoquin Cream 20% should be stored at 25°C (77°F); excursion permitted to 15°C - 30°C (59°F - 86°F). |packLabel=[[File:DailyMed - BENOQUIN- monobenzone cream .png|thumb|none|400px|This image is provided by the National Library of Medicine.] |fdaPatientInfo=There is limited information regarding Patient Counseling Information of Monobenzone in the drug label.

|alcohol=* Alcohol-Monobenzone interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=* BENOQUIN®

|drugShortage= }} {{#subobject:

 |Label Page=Monobenzone
 |Label Name=DailyMed - BENOQUIN- monobenzone cream .png

}}

}}